SpyGlass Pharma, Inc. (SGP)
| Market Cap | $1.05B+31.1% |
| Revenue (ttm) | n/a |
| Net Income | -$70.49M |
| EPS | -$2.70 |
| Shares Out | 33.46M |
| PE Ratio | n/a |
| Forward PE | -10.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,301 |
| Open | $32.09 |
| Previous Close | $32.24 |
| Day's Range | $30.53 - $32.81 |
| 52-Week Range | $17.06 - $39.92 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | $46.67(+48.29%) |
| Earnings Date | Nov 12, 2026 |
About SGP
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades only$SGP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in SGP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SGP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SGP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SGP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SGP from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from SGP’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings report and investor conference participation signal active execution; valuation concerns temper enthusiasm but don't negate operational progress.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| DMDV | AAM S&P Developed Markets High Dividend Value ETF | 1.71% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.40% |
| IVSX | Applied Finance IVS International SMID ETF | 0.81% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.73% |
| BYRE | Principal Real Estate Active Opportunities ETF | 0.27% |
| PQIN | PGIM Quant Solutions Strategic Alpha International Equity ETF | 0.22% |
| PXUS | Principal International Adaptive Multi-Factor ETF | 0.11% |
| TNXT | T. Rowe Price Innovation Leaders ETF | 0.09% |
| IWC | iShares Micro-Cap ETF | 0.08% |
| DMRI | DeltaShares S&P International Managed Risk ETF | 0.05% |
| JHMD | John Hancock Investments - Multifactor Developed International ETF | 0.03% |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | 0.03% |
Weight is the stock’s share of each fund’s holdings.
